|
Item 7.01
|
Regulation FD Disclosure.
|
On June 12, 2019, ANI Pharmaceuticals, Inc. (the “Company,”
“we” or “us”) announced that Arthur Przybyl, President and CEO and Stephen Carey, Vice President and CFO,
will present at the Raymond James Life Sciences and MedTech Conference, which presentation will be webcast live at http://wsw.com/webcast/rj115/anip/
at 8:00 AM ET on Tuesday, June 18, 2019. The live webcast will be archived and available for 7 days, through June 25, 2019.
On June
12, 2019, we posted to our website our June 2019 Corporate Presentation. We may use this presentation in our communications or
at conferences. The presentation is available on our website, www.anipharmaceuticals.com, and is attached to this Current Report
on Form 8-K as Exhibit 99.2 and incorporated into this Item 7.01 by reference.
In accordance
with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2,
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
Forward-Looking Statements
Certain statements contained in the presentation slides furnished
with this report contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future operations, products, financial
position, operating results, prospects, pipeline or potential markets therefor, and other statements that are not historical in
nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,”
“plans,” “potential,” “future,” “believes,” “intends,” “continue,”
other words of similar meaning, derivations of such words, and the use of future dates.
Uncertainties and risks may cause our actual results to be materially
different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited
to, the risk that we may face with respect to importing raw materials, increased competition, delays or failure in obtaining product
approval from the U.S. Food and Drug Administration ("FDA"), general business and economic conditions, market trends,
product development, regulatory and other approvals and marketing.
More detailed information on these and additional factors that
could affect our actual results are described in our filings with the Securities and Exchange Commission, including our most recent
annual report on Form 10-K and quarterly reports on Form 10-Q, as well as our proxy statement/prospectus, filed with the Securities
and Exchange Commission on April 4, 2019. The forward-looking statements contained in this document are made only as of the date
of this document. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise.